Literature DB >> 7512165

Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.

S F Lacey1, B A Larder.   

Abstract

Mutation in the human immunodeficiency virus type 1 reverse transcriptase (RT) at codon 215 has been shown to play a significant role in resistance to zidovudine (AZT). Substitution of threonine with tyrosine or phenylalanine alone confers decreased susceptibility to the inhibitor. In this study we constructed a panel of 10 viruses with different amino acids at this codon, including 7 novel mutants, and assessed their susceptibilities to AZT. The majority of the new mutants were AZT sensitive, whereas the Thr-215-->Trp mutant was partially resistant (threefold less susceptible). A combination of the Thr-215-->Trp with the other AZT resistance mutations Lys-70-->Arg and Met-41-->Leu gave additive resistance. The Thr-215-->Phe virus was less AZT resistant than the Thr-215-->Tyr mutant, both on its own and when each was combined with the Met-41-->Leu mutant. These observations confirm the general hypothesis that increased bulk of the amino acid side chains at this position confers decreased AZT sensitivity. A leucine-to-valine substitution at codon 74 has previously been found to confer dideoxynucleoside resistance. We constructed mutants with five novel amino acid substitutions (Ala, Gly, Glu, Met, and Asp) at codon 74. Of these, only one (that with the Met substitution) retained enough RT activity to yield viable virus. It thus appears that there are severe structure-function constraints on the amino acid side chains at this position in the enzyme. The activities of the Leu-74-->Ala and Leu-74-->Met RT enzymes expressed in Escherichia coli appeared to have reduced susceptibility to ddGTP compared with the wild-type enzyme. The mutants described in this work may prove useful for correlation with structural studies of the human immunodeficiency virus type 1 RT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512165      PMCID: PMC236837     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  11 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

3.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

4.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

5.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.

Authors:  J L Martin; J E Wilson; R L Haynes; P A Furman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.

Authors:  B A Larder; B Chesebro; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

8.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

9.  Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.

Authors:  E Arnold; A Jacobo-Molina; R G Nanni; R L Williams; X Lu; J Ding; A D Clark; A Zhang; A L Ferris; P Clark
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

10.  Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

Authors:  S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; S D Kemp; B A Larder
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

View more
  14 in total

Review 1.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

Review 2.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

4.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.

Authors:  J Goudsmit; A De Ronde; D D Ho; A S Perelson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.

Authors:  P Kosalaraksa; M F Kavlick; V Maroun; R Le; H Mitsuya
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Adviye A Tolun; Ingrid Pfeifer; Antero G So; John W Mellors; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.

Authors:  J G García-Lerma; P J Gerrish; A C Wright; S H Qari; W Heneine
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

9.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

10.  Hidden messages in the nef gene of human immunodeficiency virus type 1 suggest a novel RNA secondary structure.

Authors:  Ofer Peleg; Edward N Trifonov; Alexander Bolshoy
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.